Evaluating Lanreotide to Prevent Pancreatic Complications Before Surgery

Recruiting · Phase 3 · Pancreatic Carcinoma and related conditions · 29 states

Check if I qualify View on ClinicalTrials.gov

About this trial

This study looks at whether lanreotide can help prevent a complication called a pancreatic fistula in patients with pancreatic cancer or a related condition. A pancreatic fistula can happen after surgery when there is a small leak from the pancreas. This trial compares using lanreotide before surgery to just having the surgery. The goal is to see if lanreotide can lower the chances of developing a pancreatic fistula after surgery.

The trial's ID number is NCT06807437. This is a Phase 3 trial, which means it is looking at how well lanreotide works and how safe it is. Approximately 274 people are expected to participate, and the trial is regulated by the FDA.

Who can join

Adults aged 18 and older can join if they have confirmed pancreatic cancer or a related lesion. Participants must be scheduled for a specific type of surgery within 60 days. Those with certain medical conditions or treatments in the past 180 days may not be eligible. The trial team will confirm eligibility before enrollment.

Conditions

Pancreatic Carcinoma, Pancreatic Neoplasm

Age group

Adult, Older adult

Sex

All sexes

The study team makes the final call on eligibility.

What happens in the study

Participants will be randomly assigned to one of two groups. One group will receive lanreotide before surgery, while the other group will receive a saline placebo (a harmless solution). Everyone will have blood samples taken before and after surgery. The study will track how many participants develop a pancreatic fistula and how long they stay in the hospital after surgery.